Ottawa, Ontario – (Marketwired – October 4, 2016) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP), through its subsidiary, PhytoPain Pharma Inc. (“PPP”), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that it received a PRE-IND Acknowledgement and Meeting Request Granted letter from the US FDA.